Bionano Genomics Acquires Lineagen to Facilitate the Clinical Adoption of Saphyr for Digital Cytogenetics

 Bionano Genomics Acquires Lineagen to Facilitate the Clinical Adoption of Saphyr for Digital Cytogenetics

Bionano Genomics Acquires Lineagen to Facilitate the Clinical Adoption of Saphyr for Digital Cytogenetics

Shots:

  • Lineagen to receive $9.6M consisting of 6,167,510 shares of Bionano’s common stock, ~ $1.7M in cash and assumption of ~$2.9M in liabilities. The acquisition complements Binano by adding leading cytogeneticists, genetic counselors, laboratory operations and billing experts, clinical commercialization experts, and payor contracts
  • The acquisition expands Bionano’s Saphyr genome imaging platform by adding Lineagen’s diagnostics services business based on a menu of LDTs and other services performed in a CLIA-certified environment serving a $1B market
  • The addition of Lineagen gives Bionano a unique combination of centralized and decentralized solutions for genomics research and clinical genomics to support revenue growth

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Arup Laboratories

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post